Trial
NCT01261767
First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Novo Nordisk A/S
Collaborators
—
Condition
Inflammation
Intervention
anti-IL-20
Why stopped
Trial discontinued due to apparent lack of response in psoriasis measures. No safety concerns were present
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-09